Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402.
Pahwa
Savita
S
Muresan
Petronella
P
Sleasman
John
J
Fenton
Terry
T
Moye
John
J
Deveikis
Audra
A
Wara
Diane
D
Van Dyke
Russ
R
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002648:Child; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects
D019380:Anti-HIV Agents; D007166:Immunosuppressive Agents; D007376:Interleukin-2